DS-8201a Versus T-DM1 for Human Epidermal Growth Factor Receptor 2 (HER2)-Positive, Unresectable and/or Metastatic Breast Cancer Previously Treated With Trastuzumab and Taxane [DESTINY-Breast03]
This important study, called DESTINY-Breast03, is looking into two different medicines for a type of breast cancer called HER2-positive breast cancer. This is for cancer that has spread or cannot be removed by surgery, and where patients have already received treatments like trastuzumab and a taxane. The main goal is to see if one medicine, trastuzumab deruxtecan, is better than another, trastuzumab emtansine (T-DM1), at fighting the cancer. The researchers will also carefully check if the medicines are safe and how well patients respond. This could help doctors decide the best way to treat this type of breast cancer in the future.
Auf einen Blick
Ergebnisse
Ergebnisse dieser Studie
Veröffentlicht April 2022Die Ergebnisse dieser Studie wurden veröffentlicht.
Worum geht es in dieser Studie?
This study, known as DESTINY-Breast03, is focused on improving treatments for a specific type of breast cancer. Cancer cells sometimes have a protein called HER2 on their surface. If your cancer has a lot of this protein, it's called HER2-positive breast cancer. This study is for people whose HER2-positive breast cancer has spread to other parts of the body (metastatic) or cannot be removed by surgery (unresectable).
If you're considering this study, it's because your cancer has already been treated with certain medicines in the past, specifically trastuzumab and a type of chemotherapy called a taxane. The study wants to compare two different medicines: trastuzumab deruxtecan and trastuzumab emtansine (T-DM1). Both are targeted treatments, meaning they are designed to specifically attack HER2-positive cancer cells.
By comparing these two treatments, the doctors hope to find out which one works better at shrinking or controlling the cancer and which one has a more manageable safety profile. This information is vital for helping future patients with HER2-positive breast cancer get the most effective treatment possible. Participating in a study like this helps advance medical knowledge and improve care for others.
Wichtige Erkenntnisse
- This study is for advanced HER2-positive breast cancer.
- It compares two targeted treatments: trastuzumab deruxtecan and T-DM1.
- Participants must have already received trastuzumab and a taxane.
- The goal is to find out which treatment works best and is safest.
- You'll be closely monitored with regular visits and tests.
Wer könnte berechtigt sein?
To join this study, you need to be an adult aged 18 or over with breast cancer that has been identified as HER2-positive. Your cancer must have either spread to other parts of your body or be a type that doctors cannot remove with surgery. You would also need to have received previous treatments for your cancer, including trastuzumab and a type of chemotherapy called a taxane.
Doctors will also need to see that your cancer has shown signs of growing or spreading since your last treatment. They will examine your most recent tumour tissue to confirm it is HER2-positive, and if a sample isn't available, you might need a new tiny sample (biopsy) taken. You must also have at least one area of cancer that can be measured on scans.
There are some reasons why you might not be able to join. For example, if you've already had a specific anti-HER2 treatment called an ADC (like T-DM1) for your advanced cancer. Also, if you have certain heart conditions that are not well-controlled, such as a recent heart attack or certain types of heart failure, you might not be eligible.
Könnte diese Studie für Sie geeignet sein?
Beantworten Sie diese kurzen Fragen, um zu sehen, ob Sie möglicherweise berechtigt sind. Dies ist nur ein Leitfaden – das Forschungsteam trifft die endgültige Entscheidung.
- Sind Sie 18 Jahre alt oder älter?
- Do you have HER2-positive breast cancer that has spread or can't be removed by surgery?
- Have you already been treated with trastuzumab and a taxane for your cancer?
- Has your cancer shown signs of growing or spreading since your last treatment?
- Do you have a heart condition that is well-controlled?
- Have you *not* had another ADC anti-HER2 treatment (like T-DM1) for your advanced cancer?
Was beinhaltet die Teilnahme?
If you decide to take part in this study, you would receive one of the two study treatments. You'd have regular visits with the study team to monitor your health, check for any side effects, and see how the treatment is working. These visits would likely involve physical exams, blood tests, and scans (like X-rays or CT scans) to measure your cancer.
The treatment would be given on a regular schedule, and the study team would explain exactly how and when you'd receive it. You'd continue participating for as long as the treatment is helping you and you're not experiencing severe side effects. Following the active treatment period, there would be a follow-up phase where the study team would continue to check on your health over time, even after you stop receiving the study medication. The total duration of your participation would involve the treatment period and then a period of follow-up.
Potenzielle Risiken und Vorteile
Locations (164)
- UCLA Hematology OncologyVerifizierte PostleitzahlLos Angeles, Vereinigte Staaten
- Sharp Memorial HospitalVerifizierte PostleitzahlSan Diego, Vereinigte Staaten
- Universität von Kalifornien San FranciscoVerifizierte PostleitzahlSan Francisco, Vereinigte Staaten
- Innovative Clinical Research InstituteVerifizierte PostleitzahlWhittier, Vereinigte Staaten
- Washington Cancer InstituteVerifizierte PostleitzahlWashington D.C., Vereinigte Staaten
- Florida Cancer Specialists-BroadwayVerifizierte PostleitzahlFort Myers, Vereinigte Staaten
- Florida Cancer Specialists NORTHVerifizierte PostleitzahlSt. Petersburg, Vereinigte Staaten
- Piedmont Cancer Institute, PCVerifizierte PostleitzahlAtlanta, Vereinigte Staaten
- Loyola University Health SystemVerifizierte PostleitzahlMaywood, United States
- Norton Cancer InstituteVerifizierte PostleitzahlLouisville, Vereinigte Staaten
- Dana-Farber Cancer InstituteVerifizierte PostleitzahlBoston, Vereinigte Staaten
- University of Nebraska Medical CenterVerifizierte PostleitzahlOmaha, United States
Häufige Fragen
What is HER2-positive breast cancer?
HER2-positive breast cancer means the cancer cells have a lot of a protein called HER2 on their surface. This protein can help cancer cells grow, so treatments often target it.
What does 'unresectable or metastatic' mean?
Unresectable means the cancer cannot be completely removed by surgery. Metastatic means the cancer has spread from where it started to other parts of the body.
What are trastuzumab and a taxane?
These are common treatments for HER2-positive breast cancer. Trastuzumab is a targeted drug, and a taxane is a type of chemotherapy.
Wie lange wird die Studie dauern?
The study will involve a period of receiving treatment and then a follow-up period to monitor your health over time. Your study team can give you more specific details based on your situation.
Will I know which treatment I am getting?
In some studies, you might not know which treatment you are receiving (this is called 'blinding'). The study team will explain how this particular study is designed and what to expect.
Wie Sie mehr erfahren können
Sprechen Sie immer mit Ihrem Hausarzt oder Spezialisten, bevor Sie sich entscheiden, an einer Studie teilzunehmen.
Diskussion
Community-Diskussion
Bereitgestellt von unserem Forum bei community.patient.info. Bitte seien Sie respektvoll — dies ist kein medizinischer Rat.